Nature Communications (Jan 2021)
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Eileen M. Boyle,
- Shayu Deshpande,
- Ruslana Tytarenko,
- Cody Ashby,
- Yan Wang,
- Michael A. Bauer,
- Sarah K. Johnson,
- Christopher P. Wardell,
- Sharmilan Thanendrarajan,
- Maurizio Zangari,
- Thierry Facon,
- Charles Dumontet,
- Bart Barlogie,
- Arnaldo Arbini,
- Even H. Rustad,
- Francesco Maura,
- Ola Landgren,
- Fenghuang Zhan,
- Frits van Rhee,
- Carolina Schinke,
- Faith E. Davies,
- Gareth J. Morgan,
- Brian A. Walker
Affiliations
- Eileen M. Boyle
- Myeloma Center, University of Arkansas for Medical Sciences
- Shayu Deshpande
- Myeloma Center, University of Arkansas for Medical Sciences
- Ruslana Tytarenko
- Myeloma Center, University of Arkansas for Medical Sciences
- Cody Ashby
- Myeloma Center, University of Arkansas for Medical Sciences
- Yan Wang
- Myeloma Center, University of Arkansas for Medical Sciences
- Michael A. Bauer
- Myeloma Center, University of Arkansas for Medical Sciences
- Sarah K. Johnson
- Myeloma Center, University of Arkansas for Medical Sciences
- Christopher P. Wardell
- Myeloma Center, University of Arkansas for Medical Sciences
- Sharmilan Thanendrarajan
- Myeloma Center, University of Arkansas for Medical Sciences
- Maurizio Zangari
- Myeloma Center, University of Arkansas for Medical Sciences
- Thierry Facon
- Service des maladies du sang. Hôpital Claude Huriez, Lille University Hospital
- Charles Dumontet
- INSERM 1052/CNRS 5286 Cancer Research Center of Lyon
- Bart Barlogie
- Division of Hematology, The Mount Sinai Hospital
- Arnaldo Arbini
- Perlmutter Cancer Center, NYU Langone Health
- Even H. Rustad
- Perlmutter Cancer Center, NYU Langone Health
- Francesco Maura
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Ola Landgren
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Fenghuang Zhan
- Myeloma Center, University of Arkansas for Medical Sciences
- Frits van Rhee
- Myeloma Center, University of Arkansas for Medical Sciences
- Carolina Schinke
- Myeloma Center, University of Arkansas for Medical Sciences
- Faith E. Davies
- Perlmutter Cancer Center, NYU Langone Health
- Gareth J. Morgan
- Perlmutter Cancer Center, NYU Langone Health
- Brian A. Walker
- Division of Hematology Oncology, Indiana University
- DOI
- https://doi.org/10.1038/s41467-020-20524-2
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Progression from asymptomatic smoldering multiple myeloma (SMM) to symptomatic Multiple Myeloma occurs at different rates in different patients. Here, the authors report fewer NRAS and FAM46C mutations and adverse translocations in SMM compared to MM, while KRAS mutations are associated with a shorter time to progression.
